Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + Chemotherapy + Immunotherapy in PD-L1+ Metastatic TNBC
NCT05233696Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, paclitaxel, Paclitaxel Micelles for Injection in triple-negative breast cancer (TNBC), sponsored by University of Colorado Denver. Planned start Jan 2022; status: withdrawn.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05233696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233696.